SE0201659D0 - Modified release pharmaceutical formulation - Google Patents

Modified release pharmaceutical formulation

Info

Publication number
SE0201659D0
SE0201659D0 SE0201659A SE0201659A SE0201659D0 SE 0201659 D0 SE0201659 D0 SE 0201659D0 SE 0201659 A SE0201659 A SE 0201659A SE 0201659 A SE0201659 A SE 0201659A SE 0201659 D0 SE0201659 D0 SE 0201659D0
Authority
SE
Sweden
Prior art keywords
modified release
release pharmaceutical
pharmaceutical formulation
sup
sub
Prior art date
Application number
SE0201659A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Magnusson
Mikael Thune
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201659A priority Critical patent/SE0201659D0/xx
Publication of SE0201659D0 publication Critical patent/SE0201659D0/xx
Priority to JP2004508782A priority patent/JP4603353B2/ja
Priority to CNB038124920A priority patent/CN100402025C/zh
Priority to SG200608336-4A priority patent/SG165162A1/en
Priority to NZ549176A priority patent/NZ549176A/en
Priority to RU2004132856/15A priority patent/RU2352323C2/ru
Priority to AU2003232870A priority patent/AU2003232870B2/en
Priority to BR0311460-0A priority patent/BR0311460A/pt
Priority to PCT/SE2003/000858 priority patent/WO2003101424A1/en
Priority to US10/516,420 priority patent/US7202236B2/en
Priority to PL03374299A priority patent/PL374299A1/xx
Priority to NZ536621A priority patent/NZ536621A/en
Priority to MXPA04011914A priority patent/MXPA04011914A/es
Priority to RU2008142261/15A priority patent/RU2474416C2/ru
Priority to CA2485535A priority patent/CA2485535C/en
Priority to EP03728205A priority patent/EP1513495A1/en
Priority to KR1020047019336A priority patent/KR101166921B1/ko
Priority to CN200810099130XA priority patent/CN101264051B/zh
Priority to ARP030101934A priority patent/AR039936A1/es
Priority to TW097139255A priority patent/TWI319318B/zh
Priority to TW092114767A priority patent/TWI319317B/zh
Priority to EG2003111045A priority patent/EG24479A/xx
Priority to SA3240402A priority patent/SA03240402B1/ar
Priority to NO20044767A priority patent/NO20044767L/no
Priority to IL16502904A priority patent/IL165029A0/xx
Priority to ZA200409234A priority patent/ZA200409234B/en
Priority to IS7564A priority patent/IS7564A/is
Priority to JP2009183614A priority patent/JP2009298795A/ja
Priority to AU2009243524A priority patent/AU2009243524A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0201659A 2002-05-31 2002-05-31 Modified release pharmaceutical formulation SE0201659D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE0201659A SE0201659D0 (sv) 2002-05-31 2002-05-31 Modified release pharmaceutical formulation
CN200810099130XA CN101264051B (zh) 2002-05-31 2003-05-27 改性释放的药物制剂
MXPA04011914A MXPA04011914A (es) 2002-05-31 2003-05-27 Formulacion farmaceutica de liberacion modificada.
CA2485535A CA2485535C (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
SG200608336-4A SG165162A1 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
NZ549176A NZ549176A (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
RU2004132856/15A RU2352323C2 (ru) 2002-05-31 2003-05-27 Фармацевтический препарат с модифицированным высвобождением
AU2003232870A AU2003232870B2 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
BR0311460-0A BR0311460A (pt) 2002-05-31 2003-05-27 Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
PCT/SE2003/000858 WO2003101424A1 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
US10/516,420 US7202236B2 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
PL03374299A PL374299A1 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
NZ536621A NZ536621A (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
JP2004508782A JP4603353B2 (ja) 2002-05-31 2003-05-27 調節放出型の医薬配合物
RU2008142261/15A RU2474416C2 (ru) 2002-05-31 2003-05-27 Фармацевтическая композиция с модифицированным высвобождением и ее применение
CNB038124920A CN100402025C (zh) 2002-05-31 2003-05-27 改性释放的药物制剂
EP03728205A EP1513495A1 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation
KR1020047019336A KR101166921B1 (ko) 2002-05-31 2003-05-27 개질된 방출 약학 제제
TW092114767A TWI319317B (en) 2002-05-31 2003-05-30 Modified release pharmaceutical formulation
ARP030101934A AR039936A1 (es) 2002-05-31 2003-05-30 Formulacion farmaceutica de liberacion modificada
TW097139255A TWI319318B (en) 2002-05-31 2003-05-30 Modified release pharmaceutical formulation
EG2003111045A EG24479A (en) 2002-05-31 2003-11-22 Modified release pharmaceutical formulation
SA3240402A SA03240402B1 (ar) 2002-05-31 2003-11-30 صياغة صيدلانية معدلة الاطلاق
NO20044767A NO20044767L (no) 2002-05-31 2004-11-03 Farmasoytisk formulering med modifisert frigjoring
IL16502904A IL165029A0 (en) 2002-05-31 2004-11-04 Modified release pharmaceutical formulation
ZA200409234A ZA200409234B (en) 2002-05-31 2004-11-17 Modified release pharmaceutical formulation.
IS7564A IS7564A (is) 2002-05-31 2004-11-29 Lyfjablanda með breytta losun
JP2009183614A JP2009298795A (ja) 2002-05-31 2009-08-06 調節放出型の医薬配合物
AU2009243524A AU2009243524A1 (en) 2002-05-31 2009-12-04 Modified release pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201659A SE0201659D0 (sv) 2002-05-31 2002-05-31 Modified release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE0201659D0 true SE0201659D0 (sv) 2002-05-31

Family

ID=20288037

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201659A SE0201659D0 (sv) 2002-05-31 2002-05-31 Modified release pharmaceutical formulation

Country Status (23)

Country Link
US (1) US7202236B2 (zh)
EP (1) EP1513495A1 (zh)
JP (2) JP4603353B2 (zh)
KR (1) KR101166921B1 (zh)
CN (2) CN101264051B (zh)
AR (1) AR039936A1 (zh)
AU (2) AU2003232870B2 (zh)
BR (1) BR0311460A (zh)
CA (1) CA2485535C (zh)
EG (1) EG24479A (zh)
IL (1) IL165029A0 (zh)
IS (1) IS7564A (zh)
MX (1) MXPA04011914A (zh)
NO (1) NO20044767L (zh)
NZ (1) NZ536621A (zh)
PL (1) PL374299A1 (zh)
RU (2) RU2474416C2 (zh)
SA (1) SA03240402B1 (zh)
SE (1) SE0201659D0 (zh)
SG (1) SG165162A1 (zh)
TW (2) TWI319318B (zh)
WO (1) WO2003101424A1 (zh)
ZA (1) ZA200409234B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2006075965A1 (en) 2005-01-17 2006-07-20 Gyros Patent Ab A method for detecting an at least bivalent analyte using two affinity reactants
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20080317791A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Kappa Carrageenan
US20080317927A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Process for Treatment of Kappa Carrageenan
US20080317926A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Carrageenan Process
US20080317790A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Process for Treatment of Kappa Carrageenan
US8268808B2 (en) * 2007-06-25 2012-09-18 Cp Kelco U.S., Inc. Carrageenan and carrageenan-containing products
US20080317789A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Carrageenan Process
EP2181116A4 (en) * 2007-06-25 2013-02-27 Cp Kelco Us Inc CARRAGEENAN
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
MX2010003928A (es) 2007-10-11 2010-09-10 Philip Morris Prod Producto de tabaco sin humo.
US9125434B2 (en) 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
CA2706600A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US8293285B2 (en) * 2008-03-14 2012-10-23 Cp Kelco U.S., Inc. Carrageenan modified by ion-exchange process
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
MX2019002999A (es) 2016-09-15 2019-07-18 Camurus Ab Formulaciones de analogo de prostaciclina.

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
AU600226B2 (en) 1985-02-04 1990-08-09 Merrell Pharmaceuticals Inc. Novel peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
TW201303B (zh) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
AU663169B2 (en) 1992-03-04 1995-09-28 Gyogyszerkutato Intezet Kft New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (zh) 1992-03-06 1994-05-11 Hoffmann La Roche
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301912D0 (sv) * 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
NZ302649A (en) * 1995-02-17 2000-01-28 Basf Ag Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
EP0820453A4 (en) 1995-04-04 2001-08-29 Merck & Co Inc THROMBIN INHIBITORS
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
AU3496297A (en) 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
US6331309B1 (en) 1998-09-04 2001-12-18 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
CN1170842C (zh) * 1999-01-13 2004-10-13 阿斯特拉曾尼卡有限公司 新的脒基苄基胺衍生物及其作为凝血酶抑制剂的用途
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
ATE407116T1 (de) 2000-08-16 2008-09-15 Astrazeneca Ab Neue amidino-derivate und deren verwendung als thrombin-inhibitoren
SE0003125D0 (sv) 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
SE0102921D0 (sv) * 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA78195C2 (uk) 2001-08-30 2007-03-15 Astrazeneca Ab Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts

Also Published As

Publication number Publication date
NZ536621A (en) 2006-10-27
CN101264051B (zh) 2010-12-22
RU2474416C2 (ru) 2013-02-10
CN1655761A (zh) 2005-08-17
EP1513495A1 (en) 2005-03-16
CA2485535A1 (en) 2003-12-11
IL165029A0 (en) 2005-12-18
RU2352323C2 (ru) 2009-04-20
SA03240402B1 (ar) 2008-03-23
IS7564A (is) 2004-11-29
ZA200409234B (en) 2005-07-12
RU2004132856A (ru) 2005-08-10
KR20050010013A (ko) 2005-01-26
CN101264051A (zh) 2008-09-17
JP2005536472A (ja) 2005-12-02
JP4603353B2 (ja) 2010-12-22
RU2008142261A (ru) 2010-05-10
AU2009243524A1 (en) 2009-12-24
CA2485535C (en) 2011-05-10
JP2009298795A (ja) 2009-12-24
TWI319318B (en) 2010-01-11
EG24479A (en) 2009-08-03
US20050171083A1 (en) 2005-08-04
TW200913989A (en) 2009-04-01
PL374299A1 (en) 2005-10-03
TW200403992A (en) 2004-03-16
WO2003101424A1 (en) 2003-12-11
SG165162A1 (en) 2010-10-28
NO20044767L (no) 2005-02-25
KR101166921B1 (ko) 2012-07-23
AU2003232870B2 (en) 2009-09-10
MXPA04011914A (es) 2005-03-31
AR039936A1 (es) 2005-03-09
CN100402025C (zh) 2008-07-16
BR0311460A (pt) 2005-03-29
US7202236B2 (en) 2007-04-10
AU2003232870A1 (en) 2003-12-19
TWI319317B (en) 2010-01-11

Similar Documents

Publication Publication Date Title
SE0201659D0 (sv) Modified release pharmaceutical formulation
SE0202463D0 (sv) Novel compounds
TNSN03110A1 (en) Azaindoles.
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
SE0401971D0 (sv) Piperidne derivatives
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0401970D0 (sv) Novel compounds
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE9903997D0 (sv) New compounds
SE0201658D0 (sv) Immediate release pharmaceutical formulation
SE0104250D0 (sv) Heterocyclic compounds
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203303D0 (sv) Novel Compounds
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203300D0 (sv) Novel Compounds
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
UY27587A1 (es) Heterociclos terapéuticos
SE0400285D0 (sv) Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
SE0301445D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof